MRK · News · 20260817N

Competition and Market Share

Merck & Co., Inc. · 2026-08-17 · Importance 29 · Surprise 24

Third-party reports identify Merck’s heavy reliance on Keytruda as a competitive and product-concentration risk. Analysts warn that Keytruda’s upcoming patent expiration could expose the oncology franchise to competing products and pressure future sales. The reports do not quantify the expected revenue impact or identify specific competing drugs.

Key facts

• ABN Amro Investment Solutions increased its stake in Merck & Co., Inc. by 32.3% in the second quarter, bringing its total holdings to 309,009 shares valued at $39.71 million. source
• Analysts note the risk of heavy reliance on Keytruda as its patent expiration and competition could pressure future sales of Merck & Co., Inc. source
• Recent insider selling is a point of consideration regarding Merck & Co., Inc. source
• Plato Investment Management Ltd's article notes a promising partnership with Merck in coverage of Gilead Sciences. source
• Merck & Co., Inc. has received an average rating of "Moderate Buy" from twenty-two analysts, with a consensus 1-year price target of $135.50. source